Selective loss of kisspeptin signaling in oocytes causes progressive premature ovulatory failure.
| Title: | Selective loss of kisspeptin signaling in oocytes causes progressive premature ovulatory failure. |
|---|---|
| Authors: | Ruohonen ST; Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.; Turku Center for Disease Modeling, Turku, Finland.; Gaytan F; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Instituto Maimónides de Investigación Biomédica de Córdoba and Hospital Universitario Reina Sofia, Córdoba, Spain.; Usseglio Gaudi A; Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.; Velasco I; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Instituto Maimónides de Investigación Biomédica de Córdoba and Hospital Universitario Reina Sofia, Córdoba, Spain.; Kukoricza K; Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.; Turku Center for Disease Modeling, Turku, Finland.; Drug Research Doctoral Program, University of Turku, Turku, Finland.; Perdices-Lopez C; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Instituto Maimónides de Investigación Biomédica de Córdoba and Hospital Universitario Reina Sofia, Córdoba, Spain.; Franssen D; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Instituto Maimónides de Investigación Biomédica de Córdoba and Hospital Universitario Reina Sofia, Córdoba, Spain.; Guler I; Instituto Maimónides de Investigación Biomédica de Córdoba and Hospital Universitario Reina Sofia, Córdoba, Spain.; Mehmood A; Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Elo LL; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Ohlsson C; Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Poutanen M; Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.; Turku Center for Disease Modeling, Turku, Finland.; Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Tena-Sempere M; Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.; Turku Center for Disease Modeling, Turku, Finland.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Instituto Maimónides de Investigación Biomédica de Córdoba and Hospital Universitario Reina Sofia, Córdoba, Spain.; CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Córdoba, Spain. |
| Source: | Human reproduction (Oxford, England) [Hum Reprod] 2022 Apr 01; Vol. 37 (4), pp. 806-821. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 8701199 Publication Model: Print Cited Medium: Internet ISSN: 1460-2350 (Electronic) Linking ISSN: 02681161 NLM ISO Abbreviation: Hum Reprod Subsets: MEDLINE |
| Imprint Name(s): | Publication: Oxford, UK : Oxford University Press; Original Publication: Oxford ; Washington, DC : Published for the European Society of Human Reproduction and Embryology by IRL Press, [c1986- |
| MeSH Terms: | Kisspeptins*/genetics ; Anovulation*; Mammals/metabolism ; Oocytes/metabolism ; Animals ; Female ; Humans ; Mice ; Ovulation |
| Abstract: | Study Question: Does direct kisspeptin signaling in the oocyte have a role in the control of follicular dynamics and ovulation?; Summary Answer: Kisspeptin signaling in the oocyte plays a relevant physiological role in the direct control of ovulation; oocyte-specific ablation of kisspeptin receptor, Gpr54, induces a state of premature ovulatory failure in mice that recapitulates some features of premature ovarian insufficiency (POI).; What Is Known Already: Kisspeptins, encoded by the Kiss1 gene, are essential for the control of ovulation and fertility, acting primarily on hypothalamic GnRH neurons to stimulate gonadotropin secretion. However, kisspeptins and their receptor, Gpr54, are also expressed in the ovary of different mammalian species, including humans, where their physiological roles remain contentious and poorly characterized.; Study Design, Size, Duration: A novel mouse line with conditional ablation of Gpr54 in oocytes, named OoGpr54-/-, was generated and studied in terms of follicular and ovulatory dynamics at different age-points of postnatal maturation. A total of 59 OoGpr54-/- mice and 47 corresponding controls were analyzed. In addition, direct RNA sequencing was applied to ovarian samples from 8 OoGpr54-/- and 7 control mice at 6 months of age, and gonadotropin priming for ovulatory induction was conducted in mice (N = 7) from both genotypes.; Participants/materials, Setting, Methods: Oocyte-selective ablation of Gpr54 in the oocyte was achieved in vivo by crossing a Gdf9-driven Cre-expressing transgenic mouse line with a Gpr54 LoxP mouse line. The resulting OoGpr54-/- mouse line was subjected to phenotypic, histological, hormonal and molecular analyses at different age-points of postnatal maturation (Day 45, and 2, 4, 6 and 10-11 months of age), in order to characterize the timing of puberty, ovarian follicular dynamics and ovulation, with particular attention to identification of features reminiscent of POI. The molecular signature of ovaries from OoGpr54-/- mice was defined by direct RNA sequencing. Ovulatory responses to gonadotropin priming were also assessed in OoGpr54-/- mice.; Main Results and the Role of Chance: Oocyte-specific ablation of Gpr54 caused premature ovulatory failure, with some POI-like features. OoGpr54-/- mice had preserved puberty onset, without signs of hypogonadism. However, already at 2 months of age, 40% of OoGpr54-/- females showed histological features reminiscent of ovarian failure and anovulation. Penetrance of the phenotype progressed with age, with >80% and 100% of OoGpr54-/- females displaying complete ovulatory failure by 6- and 10 months, respectively. This occurred despite unaltered hypothalamic Gpr54 expression and gonadotropin levels. Yet, OoGpr54-/- mice had decreased sex steroid levels. While the RNA signature of OoGpr54-/- ovaries was dominated by the anovulatory state, oocyte-specific ablation of Gpr54 significantly up- or downregulated of a set of 21 genes, including those encoding pituitary adenylate cyclase-activating polypeptide, Wnt-10B, matrix-metalloprotease-12, vitamin A-related factors and calcium-activated chloride channel-2, which might contribute to the POI-like state. Notably, the anovulatory state of young OoGpr54-/- mice could be rescued by gonadotropin priming.; Large Scale Data: N/A. .; Limitations, Reasons for Caution: Conditional ablation of Gpr54 in oocytes unambiguously caused premature ovulatory failure in mice; yet, the ultimate molecular mechanisms for such state of POI can be only inferred on the basis of RNAseq data and need further elucidation, since some of the molecular changes observed in OoGpr54-/- ovaries were secondary to the anovulatory state. Direct translation of mouse findings to human disease should be made with caution since, despite the conserved expression of Kiss1/kisspeptin and Gpr54 in rodents and humans, our mouse model does not recapitulate all features of common forms of POI.; Wider Implications of the Findings: Deregulation of kisspeptin signaling in the oocyte might be an underlying, and previously unnoticed, cause for some forms of POI in women.; Study Funding/competing Interest(s): This work was primarily supported by a grant to M.P. and M.T.-S. from the FiDiPro (Finnish Distinguished Professor) Program of the Academy of Finland. Additional financial support came from grant BFU2017-83934-P (M.T.-S.; Ministerio de Economía y Competitividad, Spain; co-funded with EU funds/FEDER Program), research funds from the IVIRMA International Award in Reproductive Medicine (M.T.-S.), and EFSD Albert Renold Fellowship Programme (S.T.R.). The authors have no conflicts of interest to declare in relation to the contents of this work.; Trial Registration Number: N/A.; (© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.) |
| References: | Mol Cell Endocrinol. 2021 May 1;527:111208. (PMID: 33592287); J Endocrinol. 2016 Mar;228(3):161-70. (PMID: 26698566); Hum Reprod. 2017 Sep 1;32(9):1915-1924. (PMID: 28854728); Front Endocrinol (Lausanne). 2018 Jan 04;8:365. (PMID: 29354093); J Mol Endocrinol. 2014 Dec;53(3):R103-18. (PMID: 25312969); Hum Mol Genet. 2009 Aug 1;18(15):2813-24. (PMID: 19423553); Endocrinology. 2012 Oct;153(10):4966-77. (PMID: 22869347); J Ovarian Res. 2017 Jan 13;10(1):3. (PMID: 28086947); Fertil Steril. 2007 Apr;87(4):858-61. (PMID: 17261285); FASEB J. 2015 Sep;29(9):3806-16. (PMID: 26018678); Am J Physiol Endocrinol Metab. 2009 Mar;296(3):E520-31. (PMID: 19141682); N Engl J Med. 2003 Oct 23;349(17):1614-27. (PMID: 14573733); Endocrinology. 2014 Aug;155(8):3098-111. (PMID: 24877631); Endocrinology. 2008 May;149(5):2646-56. (PMID: 18276752); Reproduction. 2015 Oct;150(4):R137-48. (PMID: 26130815); Autoimmun Rev. 2014 Apr-May;13(4-5):427-30. (PMID: 24418305); Trends Endocrinol Metab. 2018 Jun;29(6):400-419. (PMID: 29706485); J Biol Chem. 2013 Jan 11;288(2):1250-65. (PMID: 23105095); J Neuroendocrinol. 2012 Jan;24(1):22-33. (PMID: 21951227); Sci Rep. 2017 Apr 12;7:46381. (PMID: 28401948); Biochem Biophys Res Commun. 2004 Jul 23;320(2):383-8. (PMID: 15219839); Dev Dyn. 2008 Apr;237(4):1099-111. (PMID: 18351675); Hum Reprod. 2018 Feb 1;33(2):292-302. (PMID: 29206944); Nat Commun. 2016 Jan 12;7:10055. (PMID: 26753790); Nat Protoc. 2009;4(1):44-57. (PMID: 19131956); Biol Reprod. 2001 May;64(5):1285-96. (PMID: 11319131); Reproduction. 2016 Nov;152(5):591-601. (PMID: 27581083); N Engl J Med. 2009 Feb 5;360(6):606-14. (PMID: 19196677); Orphanet J Rare Dis. 2006 Apr 06;1:9. (PMID: 16722528); Hum Mol Genet. 2010 Feb 1;19(3):397-410. (PMID: 19843540); Endocrinology. 1993 Apr;132(4):1687-91. (PMID: 8462469); Menopause. 2017 Mar;24(3):345-351. (PMID: 27749734); Endocrinology. 2007 May;148(5):2301-8. (PMID: 17255205); Endocrinology. 2015 Apr;156(4):1514-22. (PMID: 25635620); Reproduction. 2002 Nov;124(5):601-9. (PMID: 12416998); Endocrinology. 2007 Nov;148(11):5258-67. (PMID: 17702853); Front Biosci. 2007 Jan 01;12:297-307. (PMID: 17127300); Sci Rep. 2016 Jan 12;6:19206. (PMID: 26755241); Reprod Toxicol. 2012 Jun;33(3):322-30. (PMID: 22285649); Nat Commun. 2013;4:2492. (PMID: 24051579); Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10714-9. (PMID: 17563351); Endocrinology. 1999 Feb;140(2):818-26. (PMID: 9927311); Reprod Biol Endocrinol. 2005 Aug 30;3:41. (PMID: 16131403); PPAR Res. 2016;2016:4612306. (PMID: 27559343); Reprod Sci. 2016 Aug;23(8):1080-6. (PMID: 26880766); Endocrinology. 1996 Nov;137(11):4779-85. (PMID: 8895347); Reproduction. 2010 Nov;140(5):633-41. (PMID: 20716613); Reprod Domest Anim. 2017 Apr;52 Suppl 2:24-28. (PMID: 27774658); Reprod Fertil Dev. 2012;24(5):656-68. (PMID: 22697116); Endocrinology. 2006 Oct;147(10):4852-62. (PMID: 16825322); Endocrinology. 2011 Mar;152(3):1057-66. (PMID: 21239444); Reprod Toxicol. 2017 Apr;69:121-131. (PMID: 28216407); Science. 2008 Feb 1;319(5863):611-3. (PMID: 18239123); Reprod Biol Endocrinol. 2015 Dec 21;13:137. (PMID: 26691645); Biol Reprod. 2019 Oct 25;101(4):782-790. (PMID: 31317194); PLoS One. 2015 Dec 07;10(12):e0144099. (PMID: 26642206); Drug Metab Dispos. 2009 Jan;37(1):203-10. (PMID: 18854377); Reprod Biomed Online. 2007 Aug;15(2):215-9. (PMID: 17697500); J Clin Invest. 2014 Aug;124(8):3667-77. (PMID: 25036713); Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):511-23. (PMID: 24450963); N Engl J Med. 2012 Feb 16;366(7):629-35. (PMID: 22335740); Nature. 2001 May 31;411(6837):613-7. (PMID: 11385580); Endocrinology. 2012 Jan;153(1):316-28. (PMID: 22067321); Endocr Rev. 2013 Dec;34(6):766-97. (PMID: 23720297); Physiol Rev. 2012 Jul;92(3):1235-316. (PMID: 22811428); Endocrinology. 2013 Dec;154(12):4939-45. (PMID: 24092638); Fertil Steril. 1990 May;53(5):804-10. (PMID: 2110072); Biol Reprod. 2000 Apr;62(4):886-94. (PMID: 10727257); Endocr Rev. 2009 Oct;30(6):713-43. (PMID: 19770291); Endocrinology. 2014 Aug;155(8):3088-97. (PMID: 24885574); Biomolecules. 2019 Dec 17;9(12):. (PMID: 31861217); Endocrinology. 2016 May;157(5):2160-72. (PMID: 27022678); Endocrinology. 2015 Jul;156(7):2492-502. (PMID: 25856427) |
| Contributed Indexing: | Keywords: Gpr54; RNA sequencing; kisspeptins; oocyte; ovary; ovulation; ovulatory failure; premature ovarian insufficiency (POI) |
| Substance Nomenclature: | 0 (Kisspeptins) |
| Entry Date(s): | Date Created: 20220117 Date Completed: 20220405 Latest Revision: 20220604 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC8971646 |
| DOI: | 10.1093/humrep/deab287 |
| PMID: | 35037941 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't